Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
Pharmaceutics · 26.01.2023 · 15 (2) · 411
DOI: 10.3390/pharmaceutics15020411 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 26.01.2023. Verfasst von Yujeong Moon und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Korea University, Seoul 02841, Republic of Korea. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF).
Abstract (Originalsprache)
Proteolysis-targeting chimeras (PROTACs) are rapidly emerging as a potential therapeutic strategy for cancer therapy by inducing the degradation of tumor-overexpressing oncogenic proteins. They can specifically catalyze the degradation of target oncogenic proteins by recruiting E3 ligases and utilizing the ubiquitin-proteasome pathway. Since their mode of action is universal, irreversible, recyclable, long-lasting, and applicable to ‘undruggable’ proteins, PROTACs are gradually replacing the role of conventional small molecular inhibitors. Moreover, their application areas are being expanded to cancer immunotherapy as various types of oncogenic proteins that are involved in immunosuppressive tumor microenvironments. However, poor water solubility and low cell permeability considerably restrict the pharmacokinetic (PK) property, which necessitates the use of appropriate delivery systems for cancer immunotherapy. In this review, the general characteristics, developmental status, and PK of PROTACs are first briefly covered. Next, recent studies on the application of various types of passive or active targeting delivery systems for PROTACs are introduced, and their effects on the PK and tumor-targeting ability of PROTACs are described. Finally, recent drug delivery systems of PROTACs for cancer immunotherapy are summarized. The adoption of an adequate delivery system for PROTAC is expected to accelerate the clinical translation of PROTACs, as well as improve its efficacy for cancer therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Bioengineering, Korea University, Seoul 02841, Republic of Korea.
- Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
- Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Woman's University, Seoul 03760, Republic of Korea.
ORCID-Profile: Kwangmeyung Kim
Förderung
- National Research Foundation of Korea (NRF)
Zitieren
APA
Moon, Y., Jeon, S. I., Shim, M. K., & Kim, K. (2023). Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy. Pharmaceutics, 15(2), 411. https://doi.org/10.3390/pharmaceutics15020411
Vancouver
Moon Y, Jeon SI, Shim MK, Kim K. Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy. Pharmaceutics. 2023;15(2):411. doi:10.3390/pharmaceutics15020411
BibTeX
@article{Moon2023,
author = {Moon, Yujeong and Jeon, Seong Ik and Shim, Man Kyu and Kim, Kwangmeyung},
title = {Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {2},
pages = {411},
doi = {10.3390/pharmaceutics15020411}
}
EUVIMED